


University of the Philippines Manila  
The Health Sciences Center  
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** BAC4-21-030  
**End-User** Property and Supply Division  
**Project** SUPPLY & DELIVERY OF VARIOUS CONTRAST MEDIA SUPPLIES  
(FRAMEWORK AGREEMENT)

**Opening of Bids:** 20 December 2021

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
1	2,000	Pc.	Iopamidol 755 mg/mL equiv. to 370 mg iodine, 50 mL vial/bottle	1,090.56		
2	31,600	Pc.	Iopromide 370 mg/mL equiv. to 769 mg iodine, 50 mL vial	1,133.00		
3	4,080	Pc.	Iodixanol 652 mg/mL (equivalent to 320 mg iodine) solution for injection, 50 mL vial	2,130.06		
4	2,000	Pc.	Iohexol 350 mg iodine/mL, 50 mL vial (Intravascular and other parenteral routes as appropriate)	955.80		
5	3,000	Pc.	Gadobutrol 1.0 mmol/mL solution for injection, 5 mL pre-filled syringe	2,060.00		
6	500	Pc.	Gadobutrol 1.0 mmol/mL solution for injection, 15 mL vial	5,665.00		
7	100	Pc.	Gadoteric acid 0.5 mmol/mL solution for injection, 10 mL vial	2,700.00		
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP57,868,664.80</b>						

Approved by:

  
Dean VICENTE Y. BELIZARIO, JR., M.D.  
Chairperson

\_\_\_\_\_  
(Signature over Printed Name of President/Gen. Manager)

\_\_\_\_\_  
(Name & Address of Company)

**TERMS & CONDITIONS FOR THE SUPPLY AND DELIVERY OF VARIOUS CONTRAST MEDIA SUPPLIES (FRAMEWORK AGREEMENT)**

1. Indicate the **brand and packing of the item/s** offered.
2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids**. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
3. **Submit the following documents, submission should be per product,**

Proj. Ref. No. BAC4-21-030  
End-User Property and Supply Division  
Project SUPPLY & DELIVERY OF VARIOUS CONTRAST MEDIA SUPPLIES  
(FRAMEWORK AGREEMENT)

Opening of Bids: **20 December 2021**

with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).

a. **Memorandum of Agreement (MOA) and Certificate of exclusive/ authorized distributorship between the manufacturer and distributor.**

Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.

b. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).

- **The name of the respective distributor should appear on the submitted CPR of the drug.**

*Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*

c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.

d. **A notarized certificate** that it is the innovator drug (if applicable).

e. **Certificate of Good Manufacturing Process (CGMP).**

f. **Valid License to Operate (LTO).**

g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.

h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only*).

i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.

Proj. Ref. No. BAC4-21-030  
End-User Property and Supply Division  
Project SUPPLY & DELIVERY OF VARIOUS CONTRAST MEDIA SUPPLIES  
(FRAMEWORK AGREEMENT)

Opening of Bids: **20 December 2021**

- 4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**
- 5 The following must be complied with specific for **contrast media:**
  - 5.1 **For Contrast Media**
    - 5.1.1 Winning bidder for Iopromide 370mg/50mL and Iodixanol 320mg/50mL is required to provide contrast media warmer with heavy duty table top trolley. One of each will be given to the Radiology Department and Catheterization Laboratory.
    - 5.1.2 Warmer and heavy duty table top trolley should be delivered on the FIRST delivery of the item.
- 6 **New brands offered** shall be subject to further evaluation and shall require the following:
  - a. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;
  - b. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).
- 7 **For the supply and delivery of awarded drugs and medicines.**
  - 7.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.
  - 7.2 Delivery schedule (whichever is applicable):
    - a) within seven (7) calendar days
    - b) as may be called for;
    - c) staggered delivery within three (3) months
      - \* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

*Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*
  - 7.3 Deliveries shall have **at least two (2) years expiration date.**
  - 7.4 Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.
  - 7.5 Delivered **items found to be non-formulary at any given time shall**

University of the Philippines Manila  
The Health Sciences Center  
BIDS & AWARDS COMMITTEE IV (BAC IV)

Proj. Ref. No. BAC4-21-030  
End-User Property and Supply Division  
Project SUPPLY & DELIVERY OF VARIOUS CONTRAST MEDIA SUPPLIES  
(FRAMEWORK AGREEMENT)

Opening of Bids: 20 December 2021

be returned to the company and a credit memo shall be issued.

- 7.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.
- 7.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.
- 7.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.
- 7.9 It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.
- 8 **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**
- 9 Compliance with RA 9184 and other applicable laws.

Approved by:

  
Dean VICENTE Y. BELIZARIO, JR., M.D.  
Chairperson

\_\_\_\_\_  
(Signature over Printed Name of President/Gen. Manager)

\_\_\_\_\_  
(Name & Address of Company)